AFfirm™ Flt3/CD135 Mouse Monoclonal Antibody - #BF8259
Related Downloads
Protocols
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Fold/Unfold
CD 135; CD135; CD135 antigen; Fetal liver kinase 2; FL cytokine receptor; Flk 2; Flk2; Flt 3; FLT-3; Flt3; FLT3_HUMAN; FMS like tyrosine kinase 3; Fms related tyrosine kinase 3; Fms-like tyrosine kinase 3; Growth factor receptor tyrosine kinase type III; Ly-72; OTTHUMP0000004234; Receptor type tyrosine protein kinase FLT3; Stem cell tyrosine kinase 1; Stk 1; STK-1; Stk1; Tyrosine protein kinase receptor FLT3; Tyrosine-protein kinase receptor FLT3;
Immunogens
Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.
- P36888 FLT3_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMSELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKEHNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDLNVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYKLIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDGRVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS
PTMs - P36888 As Substrate
Site | PTM Type | Enzyme | Source |
---|---|---|---|
N43 | N-Glycosylation | Uniprot | |
N100 | N-Glycosylation | Uniprot | |
N151 | N-Glycosylation | Uniprot | |
Y166 | Phosphorylation | Uniprot | |
N306 | N-Glycosylation | Uniprot | |
N323 | N-Glycosylation | Uniprot | |
T343 | Phosphorylation | Uniprot | |
N351 | N-Glycosylation | Uniprot | |
N354 | N-Glycosylation | Uniprot | |
Y416 | Phosphorylation | Uniprot | |
Y572 | Phosphorylation | P36888 (FLT3) | Uniprot |
S574 | Phosphorylation | Uniprot | |
Y589 | Phosphorylation | P36888 (FLT3) | Uniprot |
Y591 | Phosphorylation | P36888 (FLT3) , P11309 (PIM1) | Uniprot |
Y597 | Phosphorylation | P36888 (FLT3) | Uniprot |
Y599 | Phosphorylation | P36888 (FLT3) | Uniprot |
K602 | Ubiquitination | Uniprot | |
K614 | Ubiquitination | Uniprot | |
K623 | Ubiquitination | Uniprot | |
Y630 | Phosphorylation | Uniprot | |
K634 | Ubiquitination | Uniprot | |
K644 | Ubiquitination | Uniprot | |
K719 | Ubiquitination | Uniprot | |
Y726 | Phosphorylation | P36888 (FLT3) | Uniprot |
T728 | Phosphorylation | Uniprot | |
S759 | Phosphorylation | Uniprot | |
Y768 | Phosphorylation | P36888 (FLT3) | Uniprot |
K772 | Ubiquitination | Uniprot | |
Y793 | Phosphorylation | P36888 (FLT3) | Uniprot |
S840 | Phosphorylation | Uniprot | |
Y842 | Phosphorylation | P36888 (FLT3) | Uniprot |
Y919 | Phosphorylation | Uniprot | |
K932 | Ubiquitination | Uniprot | |
S935 | Phosphorylation | Uniprot | |
Y955 | Phosphorylation | P36888 (FLT3) | Uniprot |
T968 | Phosphorylation | Uniprot | |
Y969 | Phosphorylation | P36888 (FLT3) | Uniprot |
S993 | Phosphorylation | Uniprot |
PTMs - P36888 As Enzyme
Substrate | Site | Source |
---|---|---|
P29353-7 (SHC1) | Y239 | Uniprot |
P29353-7 (SHC1) | Y240 | Uniprot |
P29353-7 (SHC1) | Y318 | Uniprot |
P29353 (SHC1) | Y349 | Uniprot |
P29353 (SHC1) | Y350 | Uniprot |
P29353 (SHC1) | Y427 | Uniprot |
P35222 (CTNNB1) | Y654 | Uniprot |
P36888 (FLT3) | Y572 | Uniprot |
P36888 (FLT3) | Y589 | Uniprot |
P36888 (FLT3) | Y591 | Uniprot |
P36888 (FLT3) | Y597 | Uniprot |
P36888-1 (FLT3) | Y599 | Uniprot |
P36888 (FLT3) | Y726 | Uniprot |
P36888 (FLT3) | Y768 | Uniprot |
P36888 (FLT3) | Y793 | Uniprot |
P36888 (FLT3) | Y842 | Uniprot |
P36888 (FLT3) | Y955 | Uniprot |
P36888 (FLT3) | Y969 | Uniprot |
Q15118 (PDK1) | Y243 | Uniprot |
Research Backgrounds
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
N-glycosylated, contains complex N-glycans with sialic acid.
Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane.
Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation.
Membrane>Single-pass type I membrane protein. Endoplasmic reticulum lumen.
Note: Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.
Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.
Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. Interacts with FIZ1 following ligand activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with RNF115 and RNF126 (By similarity).
(Microbial infection) Interacts with human cytomegalovirus protein UL7.
The juxtamembrane autoregulatory region is important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand. Upon tyrosine phosphorylation, it mediates interaction with the SH2 domains of numerous signaling partners. In-frame internal tandem duplications (ITDs) result in constitutive activation of the kinase. The activity of the mutant kinase can be stimulated further by FLT3LG binding.
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Research Fields
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)
· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.
· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)
· Organismal Systems > Immune system > Hematopoietic cell lineage. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.